Amneal Pharmaceuticals is seeing a significant rise in its stock price after a major acquisition.
Amneal Pharmaceuticals, Inc. Class A Common Stock (NASDAQ:AMRX) is up today, showing a 1.53% increase. This follows an impressive 8.6% gain in the previous trading session, fueled by investor optimism about the company’s recent acquisition.
Investor takeaway: The acquisition of Kashiv BioSciences positions Amneal for long-term growth, even though there are some concerns about revisions to earnings estimates.
Advertisement
Amneal Pharmaceuticals, Inc. Class A Common Stock
AMRX.US
AMRX.US
Amneal Pharmaceuticals, Inc. Class A Common Stock
WealthAwesomeMarket cap
$6.30B
P/E
34.8x
52W high
$19.26
52W low
$9.49
1W change
+4.81%
Beta
1.24
Analyst Price Targets
Based on 4 analysts covering AMRX · as of Sep 17, 2026
Wall Street analysts forecast AMRX stock price to rise 18.0% over the next 12 months.
Consensus
Buy4.25 / 5.00
Avg. Target
C$21.33
+18.0% Upside
Current Price
C$18.08
Last close
Analyst Breakdown (4 analysts)
Targets are snapshotted when they change. Unchanged figures keep their original date. Not financial advice.
Wealth Awesome Price Forecast
WA ModelStatistical 90-day price range based on AMRX's historical volatility
30-Day Vol
40.4%
Annualized
90-Day Vol
36.2%
Annualized
Trend (90d)
+39.0%
Annualized drift
90d Mean
C$21.01
Expected price
| Horizon | Expected | 68% Range (1σ) |
|---|---|---|
| 30 trading days | C$19.15 | C$16.66 – C$22.01 |
| 60 trading days | C$20.06 | C$16.47 – C$24.42 |
| 90 trading days | C$21.01 | C$16.51 – C$26.74 |
Methodology: Range is calculated using 30-day realized volatility via geometric Brownian motion (log-normal model). 68% band = ±1σ, 95% band = ±2σ. This is a statistical model, not a prediction. Past volatility does not guarantee future results. Not financial advice.
Advertisement
8.6% Surge in Last Trading Session
Amneal's stock jumped sharply in the last session, reflecting strong investor interest and confidence in the company's future.
Bull case
The acquisition of Kashiv BioSciences is expected to boost Amneal's presence in the biosimilars market, which could lead to significant revenue growth in the coming years.
Bear case
Despite the positive momentum, earnings estimates have been revised down by 23.1% over the past month, raising concerns about whether the stock can maintain its recent gains.
Advertisement
Recent Acquisition Boosts Investor Confidence
Amneal's acquisition of Kashiv BioSciences has created a global biosimilars platform, which is likely to be a key growth driver for the company through the 2030s. This strategic move has greatly increased investor confidence, as shown by the rising stock price.
Earnings Outlook and Market Reactions
While the acquisition offers an optimistic outlook, Amneal's earnings estimates have seen a significant downward revision of 23.1% in the last month. Investors should keep an eye on how this trend affects future stock performance, especially with upcoming earnings expected to show a year-over-year increase.
Best next step
Keep exploring this topic
If you want to go deeper, these are the most useful follow-up pages and tools for this topic.
Broker comparison
Best trading platforms in Canada
Compare $0-commission brokers before you act on a ticker story.
Safe cash
Best GIC rates in Canada
If the story makes you want to de-risk, compare guaranteed rates next.
HISA roundup
Best high-interest savings accounts
Keep dry powder in a no-fee savings account instead of chequing.
TFSA room
Check TFSA contribution room
Shelter the next contribution before you buy.
Advertisement
Wealth Awesome
Timely coverage of Canadian stocks, earnings, dividends, and market movers for DIY investors. Stories are checked against exchange data and public filings.
View Full Profile →✅ Reviewed by Certified Financial Professionals
This content has been reviewed by CFA® charterholders and Certified Financial Planners (CFP®) with over a decade of experience in Canadian financial markets. All information is fact-checked against official Canadian sources and regulations.
Why these credentials matter: CFA® charterholders complete 900+ hours of rigorous study in investment analysis and ethics. CFP® professionals are held to the highest standards of financial planning competency and fiduciary duty in Canada.
⚠️ Professional Disclaimer
This content is for educational purposes only and should not be considered personalized financial advice. While our team brings professional expertise, individual circumstances vary. For personalized guidance, consult with a qualified financial advisor, tax professional, or mortgage specialist.
